Nadolol: Brand change
Nadolol is changing from Apo-Nadolol to Nadolol BNM. The change will happen in October 2021.
BNM Nadolol is not currently Medsafe approved. This means it will need to be prescribed and supplied in line with section 29 of the Medicines Act. We understand that Boucher & Muir are applying to Medsafe for approval.
Prescribing and supplying a medicine under section 29
Section 29 of the Medicines Act allows for medicines that are not Medsafe approved to be prescribed and supplied to people. The medicine must be prescribed by someone registered with the Medical Council of New Zealand – e.g., doctors.
We know supplying a medicine under section 29 is not ideal. In this case, however, the alternative would be for patients to have no nadolol.
We apologise for any inconvenience this causes.
Schedule listing information
1 October 2021: Nadolol (Nadolol BNM) tab
- 40 mg (pharmacode 2621118) / pack size 100 / price $19.19
- 80 mg (pharmacode 2621126) / pack size 100 / price $30.39
- Wastage claimable.
1 March 2022: Apo-Nadolol delisted
Who to contact
If you have questions about medicine funding, email firstname.lastname@example.org